Announcement

Collapse
No announcement yet.

you have to try this for EC! Its maybe possible.

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • you have to try this for EC! Its maybe possible.

    Improvement of interstitial cystitis symptoms and problems that developed during treatment with oral IPD-1151T.

    PURPOSE:

    We examined the efficacy of Suplatast Tosilatedouble dagger (IPD-1151T), a new immunoregulator that suppresses helper T cell mediated allergic responses, including IgE production and eosinophilic inflammation for treating patients with interstitial cystitis.
    MATERIALS AND METHODS:

    A total of 14 women (average age 43.7 years) with interstitial cystitis, which was nonulcerative in 13 and ulcerative in 1, were treated with 300 mg. IPD-1151T orally daily for 12 months. All patients received laboratory assessments, including hematology (eosinophils and CD20 positive cells) and serum chemistry (IgE, and interleukin-4 (IL-4) and 5, and immunohistochemical analyses of urine leukocytes (CD45RO positive cells as a T cell marker) before treatment. These parameters were also measured 4 and 12 months after continuous treatment. The voiding chart, and interstitial cystitis symptom and problem indexes were evaluated before and after IPD-1151T treatment.
    RESULTS:

    IPD-1151T treatment for 1 year resulted in a significantly increased bladder capacity and decreased symptoms, such as urinary urgency, frequency and lower abdominal pain, in patients with nonulcerative interstitial cystitis. These effects also correlated with a reduction in blood eosinophils, CD20 positive cells and IgE, and urine CD45RO positive memory T cells. No major side effects were observed.
    CONCLUSIONS:

    Our study suggests that immunological responses are involved in the development of interstitial cystitis symptoms. IPD-1151T could be a new oral agent for treatment of voiding symptoms and bladder pain in patients with interstitial cystitis.

    http://www.ncbi.nlm.nih.gov/pubmed/11061880

    --------------------

    second tryout:

    http://en.wikipedia.org/wiki/Corticosteroid

    ---------------------

    SOURCE EC study:
    http://www.hindawi.com/journals/criu/2012/354219/


    questions: PM me.

    greets.
Working...
X